Table 2.
Summary of available best evidence on APTC events
| Treatment | Best evidence source [reference] | Patient years of exposure | Number of events | APTC(% per year) |
| Placebo | Meta-analysis of celecoxib trials [19] | 585 | 8 | 1.40 |
| Placebo | Meta-analysis of etoricoxib trials [34] | 335 | 4 | 1.20 |
| Placebo | Meta-analysis of lumiracoxib trials [20] | 614 | 6 | 1.00 |
| Placebo | Meta-analysis of rofecoxib trials [32] | 1678 | 32 | 1.90 |
| Placebo | Meta-analysis of valdecoxib trials [33] | 161 | 2 | 1.25 |
| Celecoxib | Meta-analysis of celecoxib trials [19] | 5651 | 57 | 1.10 |
| Etoricoxib | Meta-analysis of etoricoxib trials [23, 34] | 30404 | 277 | 0.91 |
| Lumiracoxib | Meta-analysis of lumiracoxib trials [20] | 7859 | 72 | 0.92 |
| Rofecoxib | Meta-analysis of rofecoxib trials [32] | 6556 | 78 | 1.19 |
| Valdecoxib | Meta-analysis of valdecoxib trials [33] | 1340 | 17 | 1.27 |
| NSAID | Meta-analysis of celecoxib trials [19] | 4386 | 54 | 1.20 |
| NSAID | Meta-analysis of etoricoxib trials [23, 34] | 27644 | 232 | 0.80 |
| NSAID | Meta-analysis of lumiracoxib trials [20] | 6805 | 55 | 0.82 |
| NSAID | Meta-analysis of rofecoxib trials [32] | 4726 | 41 | 0.87 |
| NSAID | Meta-analysis of valdecoxib trials [33] | 656 | 13 | 1.97 |
APTC – Antiplatelet Triallists Collaboration outcome of fatal and nonfatal heart attack or stroke, and cardiovascular death